Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Call for a new approach to the process of clinical trials and drug registration.

× No keyword cloud information.

15 in total

1. Prescription-event and other forms of epidemiological monitoring of side-effects in the UK.

Authors: N Dunn; R D Mann
Journal: Clin Exp Allergy Date: 1999-07 Impact factor: 5.018

2. Randomized, controlled trials, observational studies, and the hierarchy of research designs.

Authors: J Concato; N Shah; R I Horwitz
Journal: N Engl J Med Date: 2000-06-22 Impact factor: 91.245

3. A comparison of observational studies and randomized, controlled trials.

Authors: K Benson; A J Hartz
Journal: N Engl J Med Date: 2000-06-22 Impact factor: 91.245

4. The pharmaceutical industry--to whom is it accountable?

Authors: M Angell
Journal: N Engl J Med Date: 2000-06-22 Impact factor: 91.245

5. Uneasy alliance--clinical investigators and the pharmaceutical industry.

Authors: T Bodenheimer
Journal: N Engl J Med Date: 2000-05-18 Impact factor: 91.245

6. Is academic medicine for sale?

Authors: M Angell
Journal: N Engl J Med Date: 2000-05-18 Impact factor: 91.245

7. Drug trials hide conflicts for doctors.

Authors: Kurt Eichenwald; Gina Kolata
Journal: N Y Times Web Date: 1999-05-16

8. Biopharmaceutical R&D success rates and development times. A new analysis provides benchmarks for the future.

Authors: M M Struck
Journal: Biotechnology (N Y) Date: 1994-07

9. The phase II/III transition. Toward the proof of efficacy in cancer clinical trials.

Authors: M Fazzari; G Heller; H I Scher
Journal: Control Clin Trials Date: 2000-08

Review 10. Adjunctive therapy for septic shock: a review of experimental approaches.

Authors: W A Lynn; J Cohen
Journal: Clin Infect Dis Date: 1995-01 Impact factor: 9.079

3 in total

1. New approach to clinical trials and drug registration. Author's suggestions for drug approval are questionable.

Authors: S Garattini; V Bertele'
Journal: BMJ Date: 2001-08-11

2. A call to restructure the drug development process: government over-regulation and non-innovative late stage (Phase III) clinical trials are major obstacles to advances in health care.

Authors: Thomas C Jones
Journal: Sci Eng Ethics Date: 2005-10 Impact factor: 3.525

3. Fluocinolone acetonide vitreous insert for chronic diabetic macular oedema: a systematic review with meta-analysis of real-world experience.

Authors: Matteo Fallico; Andrea Maugeri; Andrew Lotery; Antonio Longo; Vincenza Bonfiglio; Andrea Russo; Teresio Avitabile; Claudio Furino; Gilda Cennamo; Martina Barchitta; Antonella Agodi; Paola Marolo; Luca Ventre; Paolo Caselgrandi; Michele Reibaldi
Journal: Sci Rep Date: 2021-02-26 Impact factor: 4.379

3 in total